4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Call for Papers in Kidney and Blood Pressure ResearchKidney Function and Omics Science

      Extended Submission Deadline: February 29, 2024

      Submit now

      • Record: found
      • Abstract: found
      • Article: found

      Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aims: Oxidative stress is one of the leading factors contributing to increased mortality in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT). Cinacalcet is now commonly used in the treatment of sHPT in patients with CKD. The aim of this study was to assess the influence of treatment with cinacalcet on the oxidative stress markers in patients on hemodialysis with sHPT. Methods: In 58 hemodialysed patients with sHPT (parathyroid hormone [PTH] > 300 pg/mL) plasma Advanced Oxidation Protein Products (AOPP), serum total antioxidant capacity – ImAnOx (TAS/TAC), serum PTH, calcium and phosphate concentrations were assessed before the first dose of cinacalcet and after 6 months of treatment. Results: Serum PTH concentration decreased significantly from 895 (748–1,070) to 384 (289–510) pg/mL after 6 months of treatment; p < 0.0001. Mean serum concentrations of ­calcium and phosphate remained stable. Plasma AOPP concentration decreased significantly from 152 (126–185) to 49 ­(43–57) µmol/L after 6 months of treatment; p < 0.0001. ImAnOx significantly increased from 260 (251–270) to 272 (264–280) µmol/L; p = 0.04. After 6 months of treatment, a significant, positive correlation was found between ImAnOx and the daily dose of cinacalcet ( r = 0.30; p = 0.02). Also, the change of serum ImAnOx during treatment with cinacalcet significantly correlated with the daily dose of cinacalcet r = 0.35; = 0.01. No significant correlations were found between plasma AOPP concentration or ImAnOx and PTH, or their changes in time. Conclusions: (1) Six-month treatment based on cinacalcet seems to reduce oxidative stress markers in maintenance hemodialysis patients with sHPT. (2) This benefit may be related rather to the direct action of cinacalcet than to the serum PTH concentration decrease.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          2018
          July 2018
          07 June 2018
          : 139
          : 4
          : 286-292
          Affiliations
          [_a] aDepartment of Nephrology, Transplantation and Internal Medicine, Katowice, Poland
          [_b] bDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
          Author notes
          *Prof. Andrzej Wiecek, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Francuska 20/24 Street, PL–40-027 Katowice (Poland), E-Mail awiecek@sum.edu.pl
          Article
          489278 Nephron 2018;139:286–292
          10.1159/000489278
          29879701
          edec83a9-aefc-4dc8-825d-edc11cd20fcf
          © 2018 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 06 January 2018
          : 13 April 2018
          Page count
          Figures: 1, Tables: 2, Pages: 7
          Categories
          Clinical Practice: Original Paper

          Cardiovascular Medicine,Nephrology
          Cinacalcet,Hemodialysis,Oxidative stress,Secondary hyperparathyroidism

          Comments

          Comment on this article